GLAXOSMITHKLINE PLC - SPONSORED ADR (GSK)

Historical Holders from Q1 2014 to Q3 2025

Symbol
GSK on NYSE
Type / Class
Equity / SPONSORED ADR
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
2,101
Holdings value
$90,693
% of all portfolios
0%
Number of holders
5
Number of sells
-1
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of GLAXOSMITHKLINE PLC - SPONSORED ADR (GSK)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 2,101 $90,693 -$13,811 $43.16 5
2025 Q2 2,421 $92,983 -$31,852,636 $38.4 5
2025 Q1 824,648 $31,946,441 -$2,420,481 $38.74 6
2024 Q4 887,129 $30,003,023 -$6,268,697 $33.82 6
2024 Q3 1,088,929 $44,429,787 -$7,404,926 $40.88 7
2024 Q2 1,269,855 $48,887,021 -$472,714 $38.5 7
2024 Q1 1,282,058 $54,906,347 +$448,256 $42.87 9
2023 Q4 1,271,429 $47,119,589 -$923,395 $37.06 8
2023 Q3 1,295,426 $46,959,843 +$724,066 $36.25 9
2023 Q2 1,287,689 $45,456,980 -$503,936 $35.64 9
2023 Q1 1,289,591 $45,884,585 +$865,145 $35.58 9
2022 Q4 1,308,867 $46,357,979 -$40,598,166 $35.14 13
2022 Q3 2,672,544 $78,738,323 -$13,603,554,693 $29.43 31
2022 Q2 319,727,097 $13,922,259,966 -$354,564,281 $43.53 823
2022 Q1 331,147,981 $14,434,394,046 +$157,492,937 $43.56 913
2021 Q4 327,398,848 $14,443,568,623 +$216,623,371 $44.1 904
2021 Q3 323,687,034 $12,374,496,080 +$151,235,014 $38.21 775
2021 Q2 319,518,252 $12,729,928,084 -$341,563,872 $39.82 787
2021 Q1 316,555,475 $11,315,271,578 +$543,119,017 $35.69 764
2020 Q4 301,924,050 $11,117,499,712 +$193,375,712 $36.8 808
2020 Q3 297,985,865 $11,216,261,663 -$400,087,020 $37.64 819
2020 Q2 305,392,766 $12,461,302,425 -$290,663,173 $40.79 829
2020 Q1 312,433,269 $11,849,433,951 +$918,476,440 $37.89 809
2019 Q4 287,890,791 $13,530,960,641 +$321,723,231 $46.99 884
2019 Q3 281,834,475 $12,033,172,248 +$121,566,391 $42.68 800
2019 Q2 279,154,423 $11,177,183,564 -$33,533,667 $40.02 795
2019 Q1 280,555,433 $11,729,766,613 +$201,281,853 $41.79 837
2018 Q4 274,187,838 $10,483,954,343 +$75,971,161 $38.21 791
2018 Q3 273,484,756 $10,984,605,175 +$214,789,671 $40.17 783
2018 Q2 268,204,669 $10,811,195,153 -$297,360,231 $40.31 781
2018 Q1 275,706,252 $10,772,901,336 +$122,331,920 $39.07 771
2017 Q4 272,953,409 $9,684,497,290 +$1,015,848,573 $35.47 753
2017 Q3 242,696,353 $9,853,287,513 +$527,077,666 $40.6 736
2017 Q2 229,641,530 $9,900,797,982 +$361,012,641 $43.12 772
2017 Q1 221,364,370 $9,335,930,183 +$526,241,074 $42.16 779
2016 Q4 208,541,052 $8,032,573,648 +$51,491,334 $38.51 756
2016 Q3 206,939,909 $8,925,884,857 -$126,122,424 $43.13 727
2016 Q2 210,014,211 $9,105,490,089 +$231,559,466 $43.34 730
2016 Q1 205,019,647 $8,343,354,550 -$335,054,699 $40.55 711
2015 Q4 215,324,536 $8,688,484,219 -$122,050,696 $40.35 708
2015 Q3 217,888,471 $8,387,394,599 -$436,511,925 $38.45 692
2015 Q2 232,446,713 $9,681,481,087 -$828,806,005 $41.65 708
2015 Q1 250,012,334 $11,538,818,302 -$115,300,210 $46.15 726
2014 Q4 253,723,186 $10,840,973,794 -$554,190,945 $42.74 717
2014 Q3 264,964,258 $12,180,367,650 -$644,954,130 $45.97 693
2014 Q2 277,974,825 $14,865,353,653 +$862,044,793 $53.48 712
2014 Q1 261,899,509 $13,992,979,930 -$180,904,383 $53.43 704